Akari Therapeutics, Plc
AKTXNASDAQHealthcareBiotechnology
Regular session
$7.55
−$0.22 · -2.83%
AKTX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
42
Neutral
Sentiment
58
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAkari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Abizer Gaslightwala
- Listed since
- Jan 6, 2014
- Employees
- 6
Market position
Day range
Current $7.55
52-week range
Current $7.55
- Open
- $8.00
- Previous close
- $7.77
- Volume
- 15.68K
- 0.03× average
- Average volume
- 566.99K
- Average daily volume
- Market cap
- 8.64M USD
- Beta
- 1.39
- Market reference 1
- 50-day average
- $10.0683
- -25.01% below average
- 200-day average
- $10.6339
- -29.00% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -4.21M USD
- EV / EBITDA
- 0.24×
- Earnings yield
- -7112.00%
- Free cash flow yield
- -4344.99%
Profitability & efficiency
- Return on equity
- -61.06%
- Return on assets
- -36.12%
- Return on invested capital
- -44.99%
Financial health
- Current ratio
- 0.44×
- Altman Z-score
- -12.89
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.82M USD | 6.98M USD | 8.02M USD | 9.56M USD | 9.13M USD |
| Selling, general, and administrative | 9.28M USD | 9.66M USD | 11.36M USD | 13.53M USD | 8.08M USD |
| Operating expenses | 17.28M USD | 21.64M USD | 16.81M USD | 23.09M USD | 17.21M USD |
| Interest income | 1K USD | 8K USD | 82K USD | 45.94K USD | 10.6K USD |
| Interest expense | 949K USD | −244K USD | — | — | — |
| Depreciation and amortization | — | 14K USD | 4K USD | 4K USD | 4.13K USD |
| Operating income | −17.28M USD | −21.64M USD | −16.81M USD | −23.09M USD | −17.21M USD |
| Net income | −17.3M USD | −19.79M USD | −10.01M USD | −17.75M USD | −17.42M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -20,800
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
- Next fiscal-year EPS consensus
- -10.67
- FY2026 · 2 analysts
- Next fiscal-year revenue consensus
- 9.58M USD
- FY2026 · 2 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
AKTX news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 31, 2026 | 1:40 | — | — |
Stock split | Aug 17, 2023 | 1:20 | — | — |
Stock split | Sep 17, 2015 | 1:10 | — | — |
Stock split | Jan 3, 2014 | 1:5 | — | — |
Effective Mar 31, 2026
1:40
Effective Aug 17, 2023
1:20
Effective Sep 17, 2015
1:10
Effective Jan 3, 2014
1:5
AKTX peers
Continue in GoAI
Research AKTXresearch.disclaimer